
Design Therapeutics Investor Relations Material
Latest events

Q4 2023
Design Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Design Therapeutics Inc
Access all reports
Design Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nucleotide repeat expansions. Their innovative approach centers on the development of GeneTAC™ gene targeted chimera small molecules. These molecules are designed to modulate the expression of disease-causing genes, offering potential treatments for a range of genetic disorders. The company's research portfolio includes projects targeting conditions such as Friedreich Ataxia, a severe progressive multi-system disease; Myotonic Dystrophy Type-1 (DM1), affecting muscle, heart, and other organs; and other nucleotide repeat expansion-driven diseases like Fragile X syndrome and Huntington disease. The company is headquartered in Carlsbad, California, and its shares are listed on the Nasdaq.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
DSGN
Country
🇺🇸 United States